Online inquiry

IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4578MR)

This product GTTS-WQ4578MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD40LG gene. The antibody can be applied in Inflammatory diseases research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000074.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 959
UniProt ID P29965
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4578MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14440MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ15554MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ3656MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ6818MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ15802MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ5176MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ1643MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ7828MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK 716155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW